 JanOne Inc. NASDAQ:JAN Scientific Advisory Board Chair, Dr. Christopher Kevil sat down with Eric Bolling, JanOnes President and Chairman and host of America This Week, to discuss the effects of the companys lead drug candidate, TV1001SR, for the treatment of peripheral artery disease PAD and associated pain. Dr. Kevil was joined by renowned pain expert, Dr. Amol Soin, and both provided their insights and perspective for an approach that treats the mechanisms of a disease process, such as in PAD, and concurrently can have significant pain relieving qualities. Of particular interest was how in prior studies TV1001SR was able to treat both the underlying condition and the associated pain with no addictive repercussions. The company believes that this could mitigate the need for prescription opioids that often come with a risk for addiction, when patients are suffering from severe pain. 